CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.4B, above the global median of $1.15B
- FinancialsAltman Z-Score 7.26: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.40BUSDvs all stocks (USD)
Revenue (TTM)
36.77MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.80xvs all stocks
52-Week Change
105.51%vs all stocks
Market Capitalization
2.40BUSDvs all stocks (USD)
Enterprise Value
2.01BUSDvs all stocks (USD)
Forward P/E
-10.45xvs Biotechnology peers
Price to Sales (TTM)
65.26xvs Biotechnology peers
Price to Book (MRQ)
5.95xvs Biotechnology peers
Enterprise to Revenue
54.78xvs Biotechnology peers
Enterprise to EBITDA
-5.70xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1041.73%vs Biotechnology peers
Return on Assets (TTM)
-40.06%vs Biotechnology peers
Return on Equity (TTM)
-80.30%vs Biotechnology peers
Revenue (TTM)
36.77MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3670USDUpdated Jul 19, 2026Quarterly Revenue Growth
-79.50%vs Biotechnology peers
Gross Profit (TTM)
-304.17MUSDvs all stocks (USD)
EBITDA (TTM)
-353.18MUSDvs all stocks (USD)
Net Income (TTM)
-341.35MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-79.47%vs Biotechnology peers
Operating Cash Flow (TTM)
-293.70MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-164.64MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
83.98MUSDFY2025 · Nov 30, 2025Operating Income
-285.67MUSDvs all stocks (USD)
Pre-tax Income
-263.70MUSDFY2025 · Nov 30, 2025Income Tax Expense
760.00KUSDFY2025 · Nov 30, 2025Net Income
-264.46MUSDFY2025 · Nov 30, 2025EBIT
-285.67MUSDFY2025 · Nov 30, 2025EBITDA (Income Statement)
-266.81MUSDFY2025 · Nov 30, 2025Research & Development
316.90MUSDFY2025 · Nov 30, 2025Selling, General & Administrative
52.74MUSDFY2025 · Nov 30, 2025Non-operating Interest Income
21.97MUSDFY2025 · Nov 30, 2025Net Income from Continuing Operations
-264.46MUSDFY2025 · Nov 30, 2025Operating Cash Flow
-250.31MUSDFY2025 · Nov 30, 2025Free Cash Flow
-264.31MUSDFY2025 · Nov 30, 2025Cash & Cash Equivalents (End of Period)
247.93MUSDFY2025 · Nov 30, 2025Starting Profit (CF Statement)
-264.46MUSDFY2025 · Nov 30, 2025Depreciation & Amortization
18.86MUSDFY2025 · Nov 30, 2025Stock-based Compensation
37.97MUSDFY2025 · Nov 30, 2025Change in Accounts Payable (CF)
-630.00KUSDFY2025 · Nov 30, 2025Change in Other Assets/Liabilities
-42.05MUSDFY2025 · Nov 30, 2025Capital Expenditures
-14.00MUSDFY2025 · Nov 30, 2025Purchase of Investments
-455.69MUSDFY2025 · Nov 30, 2025Sale of Investments
617.54MUSDFY2025 · Nov 30, 2025Net Investing Cash Flow
147.85MUSDFY2025 · Nov 30, 2025Net Financing Cash Flow
234.76MUSDFY2025 · Nov 30, 2025Shares Outstanding
103.70MSharesUpdated Jul 19, 2026Float Shares
82.79MSharesUpdated Jul 19, 2026Shares Short
17.80MSharesUpdated Jul 19, 2026Short Ratio
4.72daysvs all stocks
Short % of Shares Outstanding
17.34%vs all stocks
% Held by Insiders
1.08%vs all stocks
% Held by Institutions
114.44%vs all stocks
Total Cash (MRQ)
443.53MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.27USDUpdated Jul 19, 2026Total Debt (MRQ)
58.14MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1444xvs Biotechnology peers
Current Ratio (MRQ)
6.34xvs Biotechnology peers
Book Value per Share (MRQ)
3.88USDUpdated Jul 19, 2026Total Assets
688.13MUSDvs all stocks (USD)
Total Current Assets
606.82MUSDFY2025 · Nov 30, 2025Total Liabilities
149.39MUSDFY2025 · Nov 30, 2025Total Non-current Assets
81.32MUSDFY2025 · Nov 30, 2025Total Non-current Liabilities
62.92MUSDFY2025 · Nov 30, 2025Total Current Liabilities
86.47MUSDFY2025 · Nov 30, 2025Cash & Cash Equivalents
246.96MUSDFY2025 · Nov 30, 2025Other Short-term Investments
345.98MUSDFY2025 · Nov 30, 2025Accounts Payable
11.21MUSDFY2025 · Nov 30, 2025Short-term Debt
2.82MUSDFY2025 · Nov 30, 2025Deferred Revenue
17.58MUSDFY2025 · Nov 30, 2025Other Current Liabilities
2.10MUSDFY2025 · Nov 30, 2025Long-term Debt
52.91MUSDFY2025 · Nov 30, 2025Common Stock (Book)
102.00KUSDFY2025 · Nov 30, 2025Retained Earnings
-1.00BUSDFY2025 · Nov 30, 2025Total Shareholders' Equity
538.75MUSDvs all stocks (USD)
52-Week Low
8.20USDUpdated Jul 19, 202652-Week High
25.09USDUpdated Jul 19, 202652-Week Change
105.51%vs all stocks
Beta
1.80xvs all stocks
50-Day MA
18.91USDUpdated Jul 19, 2026200-Day MA
16.40USDUpdated Jul 19, 2026Avg 10-Day Volume
1.22MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.02MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-3.46USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 7.26: safe zoneNotable
Altman Z-Score: 7.26
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.4B, above the global median of $1.15BNotable
Market cap (USD): 2,399,432,510Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Mineralys Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Vericel Corporation
Tier 1ProductionApproval-Gated PipelineRule
BrightGene Bio-Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pell Bio-Med Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prestige Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BioCryst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharvaris N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
HUTCHMED
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule